Comparing Health Catalyst (HCAT) & The Competition

Health Catalyst (NASDAQ:HCAT) is one of 93 publicly-traded companies in the “Healthcare Technology” industry, but how does it compare to its rivals? We will compare Health Catalyst to similar companies based on the strength of its valuation, profitability, risk, earnings, dividends, institutional ownership and analyst recommendations.

Profitability

This table compares Health Catalyst and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Health Catalyst	-90.61%	-1.83%	-0.80%
Health Catalyst Competitors	-778.94%	-34.14%	-15.64%

Institutional & Insider Ownership

85.0% of Health Catalyst shares are held by institutional investors. Comparatively, 42.3% of shares of all “Healthcare Technology” companies are held by institutional investors. 19.4% of Health Catalyst shares are held by company insiders. Comparatively, 16.0% of shares of all “Healthcare Technology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Health Catalyst and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Health Catalyst	$311.14 million	-$177.97 million	-0.49
Health Catalyst Competitors	$355.95 million	-$24.15 million	13.19

Health Catalyst’s rivals have higher revenue and earnings than Health Catalyst. Health Catalyst is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Health Catalyst has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500. Comparatively, Health Catalyst’s rivals have a beta of 1.06, meaning that their average share price is 6% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Health Catalyst and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Catalyst	1	5	2	0	2.12
Health Catalyst Competitors	446	1513	2723	88	2.51

Health Catalyst presently has a consensus target price of $2.01, indicating a potential upside of 11.57%. As a group, “Healthcare Technology” companies have a potential upside of 37.19%. Given Health Catalyst’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Health Catalyst has less favorable growth aspects than its rivals.

Summary

Health Catalyst rivals beat Health Catalyst on 7 of the 13 factors compared.

Health Catalyst Company Profile

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases. It offers services expertise solutions comprising data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is headquartered in South Jordan, Utah.